Cargando…

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands

BACKGROUND: In 2012, around 400.000 patients in the Netherlands were treated with Vitamin K Antagonists (VKA) for thromboembolic diseases. Since 2011, non-VKA oral anticoagulants (NOACs) are available. NOACs do not require frequent INR monitoring which benefits patients, but also imposes a risk of r...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Heuvel, J. M., Hövels, A. M., Büller, H. R., Mantel-Teeuwisse, A. K., de Boer, A., Maitland-van der Zee, A. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905161/ https://www.ncbi.nlm.nih.gov/pubmed/29692686 http://dx.doi.org/10.1186/s12959-017-0156-y

Ejemplares similares

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
por: Escobar Cervantes, Carlos, et al.
Publicado: (2022)

Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
por: Diel, Roland, et al.
Publicado: (2019)

Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry
por: Liu, Chang, et al.
Publicado: (2019)

A comparison of the effects of NOAC and VKA therapy on the incidence of dementia in patients with atrial fibrillation: A systematic review and meta‐analysis
por: Wang, Wenjie, et al.
Publicado: (2023)

SSRI co‐medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010‐2015
por: Sheikh Rezaei, Safoura, et al.
Publicado: (2019)

Are NOACs as safe and efficient as VKA regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?
por: Magro, Pedro Lamares, et al.
Publicado: (2022)

Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations
por: Douxfils, Jonathan, et al.
Publicado: (2015)

Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
por: Geldhof, Vincent, et al.
Publicado: (2014)

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
por: Eyileten, Ceren, et al.
Publicado: (2020)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation
por: Tosetto, Alberto, et al.
Publicado: (2015)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

Alignment of CanMEDS-Based Undergraduate and Postgraduate Pharmacy Curricula in The Netherlands
por: Koster, Andries S., et al.
Publicado: (2020)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Abstract 28. Novel Oral Anticoagulants (NOACs) in Microsurgery: A Review
por: Yao, Amy, et al.
Publicado: (2017)

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
por: Douxfils, Jonathan, et al.
Publicado: (2014)

Antithrombotic therapy after mitral valve repair: VKA or aspirin?
por: van der Wall, Sake J., et al.
Publicado: (2018)

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
por: Altay, Servet, et al.
Publicado: (2017)

Case report: Application of non-VKA oral anticoagulants in patient of idiopathic hypereosinophilic syndrome with intracardiac thrombus
por: Zou, Man, et al.
Publicado: (2022)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

Séminaire Bourbaki : exposés 543-560
por: Dold, A, et al.
Publicado: (1981)

Consideration of NOACs (novel or non-vitamin K-dependent oral anticoagulants) in dental procedure
por: Song, Jiyoung
Publicado: (2021)

Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials
por: Noseworthy, Peter A., et al.
Publicado: (2017)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis
por: Udayachalerm, Sariya, et al.
Publicado: (2018)

Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what’s the current status of NOACs?
por: Milojevic, Milan, et al.
Publicado: (2022)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands
por: van den Heuvel, Jan Maurik, et al.
Publicado: (2020)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

Reversal agents for NOACs: Connecting the dots
por: Dalal, Jamshed, et al.
Publicado: (2016)

Impact of medicine shortages on patients - a framework and application in the Netherlands
por: Postma, Doerine J., et al.
Publicado: (2022)

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
por: Lindahl, Tomas L., et al.
Publicado: (2017)

Evaluating equality in prescribing Novel Oral Anticoagulants (NOACs) in England: The protocol of a Bayesian small area analysis
por: Rezaei-Darzi, Ehsan, et al.
Publicado: (2021)

Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction
por: Singh, Balbir, et al.
Publicado: (2022)

Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults—Ineffectiveness of Oral Anticoagulation Treatment with VKA
por: Panisello-Tafalla, Anna, et al.
Publicado: (2015)

DVT prophylaxis in critical care: role of NOACS
por: Lancé, Marcus D.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_92sf43jp4nemrc28uo2nca32cs